Ozone Therapy in Chemotherapy-induced Peripheral Neuropathy: RCT (O3NPIQ)

NCT04299893 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2025-09-02

No results posted yet for this study

Summary

The main objective of this clinical trial is to evaluate the effectiveness and cost-effectiveness of adding ozone therapy to the clinical management of patients with pain secondary to chemotherapy-induced peripheral neuropathy

Conditions

  • Chemotherapy-induced Peripheral Neuropathy
  • Pain, Neuropathic
  • Pain Syndrome

Interventions

DRUG

Ozone

Ozone Group: Standard treatment + Ozone therapy (O3/O2) by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.

DRUG

Oxygen

Control Group: Standard treatment + Oxygen (O2) by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.

Sponsors & Collaborators

  • Servicio Canario de Salud

    collaborator OTHER
  • Instituto de Salud Carlos III

    collaborator OTHER_GOV
  • Red de Investigación en Servicios de Salud en Enfermedades Crónicas

    collaborator OTHER
  • Fundación DISA, Spain

    collaborator UNKNOWN
  • Fundación Española del Dolor (FED)

    collaborator UNKNOWN
  • Bernardino Clavo, MD, PhD

    lead OTHER

Principal Investigators

  • Bernardino Clavo, MD, PhD · Dr. Negrín University Hospital, Las Palmas, Spain

  • Pedro G Serrano-Aguilar, MD, PhD · Servicio de Evaluación. Servicio Canario de Salud. Spain

  • Delvys Rodríguez-Abreu, MD · Complejo Hospitalario Universitario Insular Materno Infantil, Las Palmas, Spain

  • Gustavo M Callico, Prof, PhD · Institute for Applied Microelectronics, University of Las Palmas de G. C., Spain

  • Francisco Rodríguez-Esparragón, BSc, PhD · Dr. Negrín University Hospital, Las Palmas, Spain

  • Bernardino Clavo, MD, PhD · Dr. Negrín University Hospital, Las Palmas, Spain

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-30
Primary Completion
2027-09-30
Completion
2027-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04299893 on ClinicalTrials.gov